Aptus Pharma Ltd

Aptus Pharma Ltd has issued a corrigendum/addendum to its 16th Annual General Meeting (AGM) notice, originally scheduled for September 14, 2026. The correction pertains to inadvertent errors in the Explanatory Statement concerning Item No. 3, which relates to a proposed preferential issue of 16,02,870 Equity Shares. The company has provided the facility for remote e-voting through CDSL, with voting commencing on September 11, 2026, and concluding on September 13, 2026. The corrigendum was issued on September 7, 2026, and will be published in newspapers and uploaded to the company's website.

Aptus Pharma Limited is charting its next growth phase by focusing on developing its own manufacturing capabilities, strengthening its Pan-India presence, and exploring international markets. The company plans to raise ₹44.88 crore through a preferential issue of equity shares, subject to shareholder approval at the AGM on September 14, 2026. Funds will be allocated to capital expenditure (₹25 crore), working capital (₹10 crore), and general corporate purposes (₹9.88 crore). The long-term strategy includes meeting approximately 20% of product requirements through in-house manufacturing, expanding domestic sales and distribution, and exploring markets in Africa, the Middle East, and Latin America.

Aptus Pharma Ltd has submitted its Annual Report for the Financial Year 2025-26, which includes the Notice of the 16th Annual General Meeting (AGM). The AGM is scheduled to be held on September 14, 2026, at 11:00 AM IST, conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The report, compliant with SEBI regulations, is also available on the company's website. It provides a comprehensive overview of the company's financial and operational performance, strategic priorities, and industry insights, while also including standard forward-looking statements and risk disclosures.

Aptus Pharma Ltd has announced its Annual General Meeting (AGM) will be held on Monday, September 14, 2026. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of the Audited Financial Statements for the financial year ended March 31, 2026, the appointment of a director liable to retire by rotation, and the approval of a preferential allotment of equity shares. The company has also facilitated remote e-voting for its members through CDSL, with e-voting commencing on September 11, 2026, and concluding on September 13, 2026.

Aptus Pharma Ltd announced the outcome of its Board Meeting held on August 17, 2026. The board approved a preferential issue of 16,02,870 equity shares of face value ₹10 each at an issue price of ₹280 per share, aggregating to approximately ₹44.88 Crores. The meeting also took on record the valuation report, certificates from the Practicing Company Secretary and Statutory Auditor confirming compliance with SEBI ICDR Regulations and the Companies Act, 2013. Additionally, the board approved the convening of the 16th Annual General Meeting on September 14, 2026, to be held through Video Conferencing/Other Audio-Visual Means.

Aptus Pharma Ltd has announced a Board of Directors meeting scheduled for August 17, 2026, to consider and approve a preferential issue of 16,10,100 equity shares. The agenda includes taking on record the valuation report, determining the issue price based on a registered valuer's report, and approving PCS and Auditor certificates for compliance. The company will also convene its 16th Annual General Meeting on September 14, 2026. Concurrently, the trading window for designated persons and their immediate relatives will be closed from August 12, 2026, until 48 hours after the board meeting outcome is disseminated, in compliance with SEBI PIT Regulations.

Aptus Pharma Ltd has issued a clarification regarding a typographical error in the minutes of its Board meeting held on August 8, 2026. The error incorrectly stated the meeting venue as the 'registered office' instead of the 'Head Office' located at RK Trade Tower, Rajkot. Additionally, an annexure was mistakenly titled 'Annexure 1' instead of 'Annexure A'. The company assures that these are purely typographical errors and do not alter the substance or outcome of the decisions made during the meeting, which included the approval of a preferential issue of shares. The company has requested the stock exchange to take this clarification on record.

Aptus Pharma Ltd's Board of Directors has approved a preferential issue of 16,10,100 equity shares of face value Rs. 10 each. The decision was made during a board meeting held on August 8, 2026. The company will issue these shares under SEBI ICDR Regulations and the Companies Act, 2013, subject to shareholder and other necessary approvals. The 'Relevant Date' for determining the minimum price for the allotment is set as August 14, 2026. Additionally, the Board has fixed September 14, 2026, as the date for the Annual General Meeting. A registered valuer has been appointed to determine the issue price.

Aptus Pharma Ltd has announced a Board of Directors meeting scheduled for August 8, 2026. The primary agenda items include considering and approving a proposal for raising funds through the issuance of equity shares or other securities via Preferential Allotment, in compliance with SEBI ICDR Regulations and the Companies Act. Additionally, the board will discuss the closure of the trading window for designated persons and their immediate relatives, effective from August 5, 2026, until 48 hours after the dissemination of the board meeting outcome. The meeting will take place at the company's head office in Rajkot, Gujarat.

Aptus Pharma Limited's Board of Directors has approved a proposal to raise up to ₹51 crore for business expansion. The fundraising will be a combination of a preferential allotment of securities up to ₹35 crore, debt finance up to ₹10 crore, and internal accruals of ₹6 crore. The preferential allotment is subject to necessary approvals, including shareholder and regulatory clearances. The Board has delegated authority to the Managing Director to identify and negotiate with prospective investors for the preferential allotment, with final approvals to be sought in subsequent meetings.